Colorectal and GI oncology programs operate at the convergence of molecular diagnostics, complex chemotherapy regimens, procedural scheduling, and long-term surveillance. The NCCN guidelines for colorectal cancer require reflex MSI/MMR testing on all newly diagnosed tumors, comprehensive RAS/RAF molecular profiling for metastatic disease, and systematic CEA surveillance for post-resection patients. Between diagnosis and surveillance, patients require PORT-A-Cath placement for intravenous access before oxaliplatin-based chemotherapy begins. Managing all four of these administrative workflows simultaneously — while providing patient navigation and care coordination — taxes clinical staff capacity in any busy GI oncology program. Virtual assistants (VAs) trained in GI oncology operations are now handling the coordination and documentation layer of these workflows with structured, defined protocols.
MSI/MMR Reflex Testing Coordination
Universal tumor testing for mismatch repair (MMR) protein expression by immunohistochemistry, or microsatellite instability (MSI) by PCR or NGS, is now standard for all newly diagnosed colorectal cancers and recommended for endometrial, gastric, and small bowel cancers. CoC-accredited cancer programs are monitored for universal testing compliance, and NCCN guidelines tie immunotherapy eligibility for pembrolizumab in MSI-H/dMMR metastatic colorectal cancer directly to confirmed testing results.
VAs coordinate MSI/MMR reflex testing by ensuring that pathology orders for reflex testing are placed at the time of surgical pathology specimen submission, tracking result turnaround from the pathology laboratory, and notifying the oncology team when results are available. When testing is reflexed but results are delayed or unavailable — a common occurrence for outside institution specimens — VAs coordinate with referring pathology departments to obtain or repeat testing. ASCO's 2024 biomarker implementation report found that reflex testing completion rates in community colorectal programs without dedicated coordination were 14 percentage points lower than in programs with structured tracking.
KRAS, NRAS, BRAF V600E, and HER2 Result Tracking
For metastatic colorectal cancer, treatment selection depends entirely on molecular profile: RAS-wild-type tumors are eligible for anti-EGFR therapy (cetuximab, panitumumab), BRAF V600E-mutant tumors require BRAF-targeted combination therapy, and HER2-amplified tumors may be eligible for HER2-directed therapy. Any one of these mutations also affects prognosis and clinical trial eligibility. Turnaround from comprehensive molecular panels averages 10 to 14 days, and in practices seeing 5 to 10 new metastatic colorectal patients per month, 30 to 50 pending molecular results may be in circulation at any given time.
VAs maintain molecular result tracking logs, perform daily portal checks, flag incoming results for oncologist review, and confirm that all expected molecular markers have returned before the first-line treatment planning appointment. This eliminates the common scenario in which a treatment appointment proceeds with incomplete molecular data, resulting in suboptimal regimen selection or appointment delay.
PORT-A-Cath Placement Scheduling
FOLFOX, FOLFIRI, and FOLFIRINOX — the foundational chemotherapy regimens in colorectal and GI oncology — require reliable central venous access. PORT-A-Cath implantation is typically scheduled through interventional radiology or surgery, and coordinating placement ahead of the first chemotherapy infusion requires precise timing: the port must be placed, healed, and cleared for use before the first infusion date, while placement cannot be scheduled too far in advance of chemotherapy start without risk of access delays or patient inconvenience.
VAs manage PORT-A-Cath scheduling coordination: confirming the planned chemotherapy start date with the oncology team, identifying the appropriate scheduling lead time (typically 7 to 14 days pre-infusion), scheduling placement through IR or surgery, and communicating pre-procedure instructions to the patient. VAs also track placement completion and port access clearance, ensuring the infusion center is notified before the patient's first chemotherapy appointment.
CEA Surveillance Recall Management
ASCO and NCCN guidelines recommend serum CEA measurement every 3 to 6 months for 5 years following curative resection for stage II or III colorectal cancer, along with CT surveillance and colonoscopy at defined intervals. Managing a surveillance recall program for a population of 100 or more post-resection patients requires systematic tracking of each patient's surveillance schedule, proactive recall outreach, and documentation of completed or missed surveillance events.
VAs maintain the CEA surveillance registry, generate monthly recall lists, conduct patient outreach for upcoming surveillance labs and imaging, and document surveillance completion in the EHR. For practices participating in CoC's Cancer Survivorship accreditation standard, documented surveillance follow-up is a reportable quality measure that VA management directly supports.
To explore GI oncology virtual assistant support, visit Stealth Agents.
Sources
- American Society of Clinical Oncology. "Biomarker Implementation in Colorectal Cancer." 2024.
- National Comprehensive Cancer Network. "NCCN Guidelines: Colon Cancer, Rectal Cancer." 2025.
- Commission on Cancer. "CoC Universal MSI/MMR Testing Standard." facs.org. 2024.
- ASCO. "Colorectal Cancer Surveillance Guideline." asco.org.